Liver X receptor activation inhibits osteoclastogenesis by suppressing NF-κB activity and c-Fos induction and prevents inflammatory bone loss in mice

Journal of Leukocyte Biology

Volumn 94, Issue 1, 2013, Pages 99-107

  Kim, Hyun Ju ^a   Yoon, Kyung Ae ^a   Yoon, Hye Jin ^a   Hong, Jung Min ^a   Lee, Min Jung ^a   Lee, In Kyu ^b   Kim, Shin Yoon ^a,b  

^a Kyungpook National University Hospital   (South Korea)

^b Kyungpook National University School of Medicine   (South Korea)

Author keywords

Bone resorption; LPS; Osteoclast; Therapeutic target

Indexed keywords

3 [3 [[2 CHLORO 3 (TRIFLUOROMETHYL)BENZYL](2 DIPHENYLETHYL)AMINO]PROPOXY]PHENYLACETIC ACID; BIM PROTEIN; CASPASE 3; CASPASE 9; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIVER X RECEPTOR; N (2,2,2 TRIFLUOROETHYL) N [4 [2,2,2 TRIFLUORO 1 HYDROXY 1 (TRIFLUOROMETHOXY)ETHYL]PHENYL]BENZENESULFONAMIDE; OSTEOCLAST DIFFERENTIATION FACTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN C FOS; SYNAPTOPHYSIN; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR NFATC1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; DOWN REGULATION; MALE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

BONE RESORPTION; LPS; OSTEOCLAST; THERAPEUTIC TARGET;

ALVEOLAR BONE LOSS; ANIMALS; APOPTOSIS; BENZOATES; BENZYLAMINES; BLOTTING, WESTERN; BONE DEVELOPMENT; BONE MARROW CELLS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; HYDROCARBONS, FLUORINATED; IMMUNOENZYME TECHNIQUES; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED C57BL; NF-KAPPA B; NFATC TRANSCRIPTION FACTORS; ORPHAN NUCLEAR RECEPTORS; OSTEOCLASTS; PPAR GAMMA; PROTO-ONCOGENE PROTEINS C-FOS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SULFONAMIDES; TRANSCRIPTION, GENETIC;

MUS;

EID: 84879559478     PISSN: 07415400     EISSN: 19383673     Source Type: Journal    
DOI: 10.1189/jlb.1112601     Document Type: Article

References (51)

1. Anderson, D. M., Maraskovsky, E., Billingsley, W. L., Dougall, W. C., Tometsko, M. E., Roux, E. R., Teepe, M. C., DuBose, R. F., Cosman, D., Galibert, L. (1997) A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390, 175-179.
2. Lacey, D. L., Timms, E., Tan, H. L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., Hsu, H., Sullivan, J., Hawkins, N., Davy, E., Capparelli, C., Eli, A., Qian, Y. X., Kaufman, S., Sarosi, I., Shalhoub, V., Senaldi, G., Guo, J., Delaney, J., Boyle, W. J. (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93, 165-176.
3. Wong, B. R., Josien, R., Lee, S. Y., Sauter, B., Li, H. L., Steinman, R. M., Choi, Y. (1997) TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J. Exp. Med. 186, 2075-2080.
4. Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., Tsuda, E., Morinaga, T., Higashio, K., Udagawa, N., Takahashi, N., Suda, T. (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/ osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. USA 95, 3597-3602.
5. Martin, T. J., Sims, N. A. (2005) Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol. Med. 11, 76-81.
6. Boyle, W. J., Simonet, W. S., Lacey, D. L. (2003) Osteoclast differentiation and activation. Nature 423, 337-342.
7. Baron, R., Hesse, E. (2012) Update on bone anabolics in osteoporosis treatment: rationale, current status, and perspectives. J. Clin. Endocrinol. Metab. 97, 311-325.
8. Bruzzaniti, A., Baron, R. (2006) Molecular regulation of osteoclast activity. Rev. Endocr. Metab. Dis. 7, 123-139.
9. Teitelbaum, S. L. (2007) Osteoclasts: what do they do and how do they do it? Am. J. Pathol. 170, 427-435.
10. Teitelbaum, S. L., Ross, F. P. (2003) Genetic regulation of osteoclast development and function. Nat. Rev. Genet. 4, 638-649.
11. Novack, D. V., Teitelbaum, S. L. (2008) The osteoclast: friend or foe? Ann. Rev. Pathol. 3, 457-484.
12. Asagiri, M., Takayanagi, H. (2007) The molecular understanding of osteoclast differentiation. Bone 40, 251-264.
13. Tanaka, S., Nakamura, K., Takahasi, N., Suda, T. (2005) Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system. Immunol. Rev. 208, 30-49.
14. Franzoso, G., Carlson, L., Xing, L., Poljak, L., Shores, E. W., Brown, K. D., Leonardi, A., Tran, T., Boyce, B. F., Siebenlist, U. (1997) Requirement for NF-κB in osteoclast and B-cell development. Genes Dev. 11, 3482-3496.
15. Iotsova, V., Caamano, J., Loy, J., Yang, Y., Lewin, A., Bravo, R. (1997) Osteopetrosis in mice lacking NF-κB1 and NF-κB2. Nat. Med. 3, 1285-1289.
16. Wagner, E. F. (2010) Bone development and inflammatory disease is regulated by AP-1 (Fos/Jun). Ann. Rheum. Dis. 69 (Suppl. 1), i86-i88.
17. Johnson, R. S., Spiegelman, B. M., Papaioannou, V. (1992) Pleiotropic effects of a null mutation in the c-fos proto-oncogene. Cell 71, 577-586.
18. Wang, Z. Q., Ovitt, C., Grigoriadis, A. E., Mohle-Steinlein, U., Ruther, U., Wagner, E. F. (1992) Bone and haematopoietic defects in mice lacking c-fos. Nature 360, 741-745.
19. Nakashima, T., Takayanagi, H. (2011) New regulation mechanisms of osteoclast differentiation. Ann. N. Y. Acad. Sci. 1240, E13-E18.
20. Repa, J. J., Mangelsdorf, D. J. (2000) The role of orphan nuclear receptors in the regulation of cholesterol homeostasis. Ann. Rev. Cell Dev. Biol. 16, 459-481.
21. Jakobsson, T., Treuter, E., Gustafsson, J. A., Steffensen, K. R. (2012) Liver X receptor biology and pharmacology: new pathways, challenges and opportunities. Trends Pharmacol. Sci. 33, 394-404.
22. Joseph, S. B., McKilligin, E., Pei, L., Watson, M. A., Collins, A. R., Laffitte, B. A., Chen, M., Noh, G., Goodman, J., Hagger, G. N., Tran, J., Tippin, T. K., Wang, X., Lusis, A. J., Hsueh, W. A., Law, R. E., Collins, J. L., Willson, T. M., Tontonoz, P. (2002) Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc. Natl. Acad. Sci. USA 99, 7604-7609.
23. Terasaka, N., Hiroshima, A., Koieyama, T., Ubukata, N., Morikawa, Y., Nakai, D., Inaba, T. (2003) T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice. FEBS Lett. 536, 6-11.
24. Levin, N., Bischoff, E. D., Daige, C. L., Thomas, D., Vu, C. T., Heyman, R. A., Tangirala, R. K., Schulman, I. G. (2005) Macrophage liver X receptor is required for antiatherogenic activity of LXR agonists. Arterioscler. Thromb. Vasc. Biol. 25, 135-142.
25. Bradley, M. N., Hong, C., Chen, M., Joseph, S. B., Wilpitz, D. C., Wang, X., Lusis, A. J., Collins, A., Hseuh, W. A., Collins, J. L., Tangirala, R. K., Tontonoz, P. (2007) Ligand activation of LXR β reverses atherosclerosis and cellular cholesterol overload in mice lacking LXR α and apoE. J. Clin. Invest. 117, 2337-2346.
26. Joseph, S. B., Castrillo, A., Laffitte, B. A., Mangelsdorf, D. J., Tontonoz, P. (2003) Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat. Med. 9, 213-219.
27. Park, M. C., Kwon, Y. J., Chung, S. J., Park, Y. B., Lee, S. K. (2010) Liver X receptor agonist prevents the evolution of collagen-induced arthritis in mice. Rheumatology (Oxford) 49, 882-890.
28. Chintalacharuvu, S. R., Sandusky, G. E., Burris, T. P., Burmer, G. C., Nagpal, S. (2007) Liver X receptor is a therapeutic target in collageninduced arthritis. Arthritis Rheum. 56, 1365-1367.
29. Li, N., Rivera-Bermudez, M. A., Zhang, M., Tejada, J., Glasson, S. S., Collins-Racie, L. A., Lavallie, E. R., Wang, Y., Chang, K. C., Nagpal, S., Morris, E. A., Flannery, C. R., Yang, Z. (2010) LXR modulation blocks prostaglandin E2 production and matrix degradation in cartilage and alleviates pain in a rat osteoarthritis model. Proc. Natl. Acad. Sci. USA 107, 3734-3739.
30. Prawitt, J., Beil, F. T., Marshall, R. P., Bartelt, A., Ruether, W., Heeren, J., Amling, M., Staels, B., Niemeier, A. (2011) Short-term activation of liver X receptors inhibits osteoblasts but long-term activation does not have an impact on murine bone in vivo. Bone 48, 339-346.
31. Remen, K. M., Henning, P., Lerner, U. H., Gustafsson, J. A., Andersson, G. (2011) Activation of liver X receptor (LXR) inhibits receptor activator of nuclear factor κB ligand (RANKL)-induced osteoclast differentiation in an LXRβ-dependent mechanism. J. Biol. Chem. 286, 33084-33094.
32. Hong, J. M., Teitelbaum, S. L., Kim, T. H., Ross, F. P., Kim, S. Y., Kim, H. J. (2011) Calpain-6, a target molecule of glucocorticoids, regulates osteoclastic bone resorption via cytoskeletal organization and microtubule acetylation. J. Bone Miner. Res. 26, 657-665.
33. Im, S. S., Osborne, T. F. (2011) Liver X receptors in atherosclerosis and inflammation. Circ. Res. 108, 996-1001.
34. Wan, Y. (2010) PPARγ in bone homeostasis. Trends Endocrinol. Metab. 21, 722-728.
35. Wan, Y., Chong, L. W., Evans, R. M. (2007) PPAR-γ regulates osteoclastogenesis in mice. Nat. Med. 13, 1496-1503.
36. Yoshikawa, T., Ide, T., Shimano, H., Yahagi, N., Amemiya-Kudo, M., Matsuzaka, T., Yatoh, S., Kitamine, T., Okazaki, H., Tamura, Y., Sekiya, M., Takahashi, A., Hasty, A. H., Sato, R., Sone, H., Osuga, J., Ishibashi, S., Yamada, N. (2003) Cross-talk between peroxisome proliferator-activated receptor (PPAR) α and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism. I. PPARs suppress sterol regulatory element binding protein-1c promoter through inhibition of LXR signaling. Mol. Endocrinol. 17, 1240-1254.
37. Ishida, A., Fujita, N., Kitazawa, R., Tsuruo, T. (2002) Transforming growth factor-β induces expression of receptor activator of NF-κ B ligand in vascular endothelial cells derived from bone. J. Biol. Chem. 277, 26217-26224.
38. Takayanagi, H., Kim, S., Koga, T., Nishina, H., Isshiki, M., Yoshida, H., Saiura, A., Isobe, M., Yokochi, T., Inoue, J., Wagner, E. F., Mak, T. W., Kodama, T., Taniguchi, T. (2002) Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev. Cell 3, 889-901.
39. Ogawa, D., Stone, J. F., Takata, Y., Blaschke, F., Chu, V. H., Towler, D. A., Law, R. E., Hsueh, W. A., Bruemmer, D. (2005) Liver X receptor agonists inhibit cytokine-induced osteopontin expression in macrophages through interference with activator protein-1 signaling pathways. Circ. Res. 96, e59-e67.
40. Chawla, A., Boisvert, W. A., Lee, C. H., Laffitte, B. A., Barak, Y., Joseph, S. B., Liao, D., Nagy, L., Edwards, P. A., Curtiss, L. K., Evans, R. M., Tontonoz, P. (2001) A PPAR γ-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol. Cell 7, 161-171.
41. Tontonoz, P., Nagy, L., Alvarez, J. G., Thomazy, V. A., Evans, R. M. (1998) PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93, 241-252.
42. Jiang, C., Ting, A. T., Seed, B. (1998) PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 391, 82-86.
43. Kidani, Y., Bensinger, S. J. (2012) Liver X receptor and peroxisome proliferator-activated receptor as integrators of lipid homeostasis and immunity. Immunol. Rev. 249, 72-83.
44. Miyata, K. S., McCaw, S. E., Patel, H. V., Rachubinski, R. A., Capone, J. P. (1996) The orphan nuclear hormone receptor LXR α interacts with the peroxisome proliferator-activated receptor and inhibits peroxisome proliferator signaling. J. Biol. Chem. 271, 9189-9192.
45. Ghisletti, S., Huang, W., Ogawa, S., Pascual, G., Lin, M. E., Willson, T. M., Rosenfeld, M. G., Glass, C. K. (2007) Parallel SUMOylation-dependent pathways mediate gene-and signal-specific transrepression by LXRs and PPARγ. Mol. Cell 25, 57-70.
46. Yamashita, T., Yao, Z., Li, F., Zhang, Q., Badell, I. R., Schwarz, E. M., Takeshita, S., Wagner, E. F., Noda, M., Matsuo, K., Xing, L., Boyce, B. F. (2007) NF-κB p50 and p52 regulate receptor activator of NF-κB ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1. J. Biol. Chem. 282, 18245-18253.
47. Choe, S. S., Choi, A. H., Lee, J. W., Kim, K. H., Chung, J. J., Park, J., Lee, K. M., Park, K. G., Lee, I. K., Kim, J. B. (2007) Chronic activation of liver X receptor induces β-cell apoptosis through hyperactivation of lipogenesis: liver X receptor-mediated lipotoxicity in pancreatic betacells. Diabetes 56, 1534-1543.
48. Wente, W., Brenner, M. B., Zitzer, H., Gromada, J., Efanov, A. M. (2007) Activation of liver X receptors and retinoid X receptors induces growth arrest and apoptosis in insulin-secreting cells. Endocrinology 148, 1843-1849.
49. Akiyama, T., Bouillet, P., Miyazaki, T., Kadono, Y., Chikuda, H., Chung, U. I., Fukuda, A., Hikita, A., Seto, H., Okada, T., Inaba, T., Sanjay, A., Baron, R., Kawaguchi, H., Oda, H., Nakamura, K., Strasser, A., Tanaka, S. (2003) Regulation of osteoclast apoptosis by ubiquitylation of proapoptotic BH3-only Bcl-2 family member Bim. EMBO J. 22, 6653-6664.
50. Robertson, K. M., Norgard, M., Windahl, S. H., Hultenby, K., Ohlsson, C., Andersson, G., Gustafsson, J. A. (2006) Cholesterol-sensing receptors, liver X receptor α and β, have novel and distinct roles in osteoclast differentiation and activation. J. Bone Miner. Res. 21, 1276-1287.
51. Kleyer, A., Scholtysek, C., Bottesch, E., Hillienhof, U., Beyer, C., Distler, J. H., Tuckermann, J., Schett, G., Kronke, G. (2012) Liver X receptors orchestrate osteoblast/osteoclast crosstalk and counteract pathologic bone loss. J. Bone Miner. Res. 27, 2442-2451.